PDF
(Download)
|
- Saffron (Crocus sativus, Iridaceae)
- Rhodiola (Rhodiola rosea, Crassulaceae)
- Mild-to-Moderate Depression
|
Date:
06-14-2019 | HC# 111855-618
|
Re: Rhodiola and Saffron Combination Reduces Symptom Severity in Depression
Bangratz
M, Ait Abdellah A, Berlin A, et al. A preliminary assessment of a combination
of rhodiola and saffron in the management of mild–moderate depression. Neuropsychiatr Dis Treat. 2018:14:1821–1829.
doi: 10.2147/NDT.S169575.
Conventional
antidepressant medications are associated with incomplete response, low
compliance, low remission rates, high risk of relapse, substantial side
effects, low tolerability, and premature discontinuation. There is a need for
alternative therapies, particularly for patients with mild-to-moderate
depression. Clinical studies show that saffron
(Crocus sativus, Iridaceae) dried
stigmata and rhodiola (Rhodiola
rosea, Crassulaceae) root individually have antidepressant effects. The authors
hypothesize that a combination of saffron and rhodiola may be beneficial for treating depression. Hence, the purpose of
this open-label observational study was to evaluate the effect of a fixed
combination of saffron and rhodiola in patients with mild-to-moderate
depression.
Patients (n = 59, aged 18–85 years) were recruited by
general practitioners (GPs) in France who typically recommended dietary supplement
to patients suffering from mild-to-moderate depression; in other words, these practitioners
would have likely recommended alternative treatments regardless of study
participation. The study was conducted from November 2016 to March 2017.
Included patients had mild-to-moderate major depressive disorder (MDD)
according to the International
Statistical Classification of Diseases and Related Health Problems 10th
revision (ICD-10) diagnostic criteria
and had a Hamilton Rating Scale for Depression (HRSD-17) score of 8–18. Excluded
patients used antidepressants or discontinued antidepressants < 1 month prior
to study entry; had severe MDD; attempted suicide or was suicidal; had other psychiatric
disorders, such as schizophrenia, bipolar, or addiction; had a chronic disease;
used medications containing piperine or St. John's wort (Hypericum perforatum,
Hypericaceae) aerial parts; or were pregnant or lactating.
Patients were treated daily with 308 mg rhodiola
extract and 30 mg saffron extract (Phytostandard de Rhodiole et Safran; PiLeJe Laboratoire;
Paris, France) in two divided doses for six weeks. At baseline, week two, week
four, and week six, the following assessments were conducted: HRSD-17 (the
primary outcome measure), Clinical Global Impression–Severity (CGI-S), Clinical
Global Impression–Improvement (CGI-I), Hospital Anxiety and Depression Scale (HADS),
Patient Global Impression of Change (PGIC) scale, safety, and compliance. Data for
the intention-to-treat (ITT), modified ITT (mITT; patients who took at least
one dose of the study medication and attended the second visit), and per protocol
(PP) populations were analyzed. All patients who had received at least one dose
of the supplement were included in the safety analysis.
Of the 59 patients in the ITT, five were lost to
follow-up, and nine did not meet the inclusion criteria, leaving 45 patients in
the safety population. Four patients were discontinued from the study; three
patients were erroneously included, and one was lost to follow-up. Therefore,
the mITT population included 41 patients. Four patients were excluded due to
poor compliance or use of unauthorized medications, leaving 37 patients in the
PP population. The safety population (n = 45) was mostly women (82.2%), and the
mean age was 47.6 years. The mean duration of the current depressive episode
was 4.4 months. According to the HRSD score-classes, 53.7% of patients had mild
depression, and 46.3% had moderate depression at baseline.
At week six, there was a significant 58% decrease in
HRSD score compared with baseline, and 87.8% of patients had an HRSD score
improvement of ≥ 20%. The patients with the greatest improvement in HRSD had
the greatest HRSD scores at baseline; HRSD scores decreased 53.7% in patients
with mild depression and 62.9% in patients with moderate depression. Based on
the change from baseline HRSD scores, 85.4% of patients improved, 12.2% of
patients were stable, and 2.4% (1 patient) worsened. At six weeks, there was
also a significant change in the patient distribution in the HDRS score-classes
compared to baseline with 29 patients (70.7%) no longer suffering from
depression and only two patients (4.9%) still suffering from moderate
depression.
At six weeks, there was a significant 31.3% decrease
in HADS anxiety and 46.1% decrease in HADS depression compared with baseline (P<
0.0001 for both). Significant improvements were seen as early as two weeks for
HADS anxiety (P < 0.0001) and HADS depression (P < 0.05). A total of
71.8% of patients had an HADS anxiety score improvement of ≥ 20%, and 66.7% of
patients had an HADS depression score improvement of ≥ 20%. CGI-S scores
indicated that only six of the 41 patients (14.6%) were moderately or markedly
depressed at six weeks compared to 31 patients (75.6%) at baseline (P <
0.0001). Overall, GPs deemed depression was significantly improved in 32
patients (78.1%). PGIC scores indicated that 56.4%, 62.5%, and 74.4% of
patients reported feeling better after two weeks, four weeks, and six weeks,
respectively. All significant results in the mITT analyses remained significant
in the PP analyses.
Compliance was good; 76.9% of patients had no missed
doses, and 23.1% missed a few days. Six patients (13.3%) reported nine adverse
events (AEs). All AEs were mild and resolved. The AEs were dizziness (n =1), vision
blurred (n = 1), arthralgia (n = 1), lower-abdomen pain (n = 1), dry mouth (n =
1), fatigue (n = 1), nausea (n = 1), and upper-abdomen pain (n = 2).
The authors conclude that six weeks treatment with
the rhodiola and saffron fixed combination significantly decreased the severity
of depression in patients diagnosed with mild-to-moderate depression, and the
combination was well-tolerated. Acknowledged limitations of this pilot study include
the relatively short treatment duration and more importantly, the lack of a placebo
control group since a strong placebo effect is commonly observed in
antidepressant trials. The authors point out that these findings need to be
confirmed in a randomized, controlled trial. Six of the authors are employees
of the manufacturer, and the seventh is a consultant to the company.
—Heather S. Oliff, PhD
|